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Abstract
Background: The polysaccharide capsule is a major virulence factor of S. pneumoniae in diseases such as
meningitis. While some capsular serotypes are more often found in invasive disease, high case fatality rates are
associated with those serotypes more commonly found in asymptomatic colonization. We tested whether growth
patterns and capsule size in human cerebrospinal fluid depends on serotype using a clinical isolate of S.
pneumoniae and its capsule switch mutants.
Results: We found that the growth pattern differed markedly from that in culture medium by lacking the
exponential and lysis phases. Growth in human cerebrospinal fluid was reduced when strains lost their capsules.
When a capsule was present, growth was serotype-specific: high carriage serotypes (6B, 9 V, 19F and 23F) grew
better than low carriage serotypes (7F, 14, 15B/C and 18C). Growth correlated with the case-fatality rates of
serotypes reported in the literature. Capsule size in human cerebrospinal fluid also depended on serotype.
Conclusions: We propose that serotype-specific differences in disease severity observed in meningitis patients may,
at least in part, be explained by differences in growth and capsule size in human cerebrospinal fluid. This
information could be useful to guide future vaccine design.
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Background
Streptococcus pneumoniae is a leading cause of disease
ranging from mild to severe manifestations. Invasive
pneumococcal disease (IPD) includes the life-threatening
conditions of bacteraemia and meningitis, both of which
have high mortality rates [1, 2] and S. pneumoniae is
also a leading cause of pneumonia. A major virulence
factor of S. pneumoniae is the polysaccharide capsule
and, based on the biochemical properties of the capsule,
S. pneumoniae is categorized into different serotypes.
Currently, approximately 100 serotypes are known [2, 3].
Several serotypes (including 7F, 14, 15B/C and 18C) have
repeatedly been associated with invasive disease while other
serotypes (such as 6B, 9 V, 19F and 23F) are more com-
monly associated with asymptomatic colonization of the
human nasopharynx [1, 4–7]. There are also differences in
clinical outcomes and mortality rates due to different sero-
types [7–10]. The pneumococcal serotype 19F, for example,
has repeatedly been associated with meningitis and a high
case-fatality rate (CFR) [8, 9].
The pneumococcal capsule has been a target of re-
search for several decades and current vaccines are com-
posed of capsule polysaccharides. The most commonly
used, pneumococcal conjugate vaccine 13 (PCV13) and
pneumococcal polysaccharide vaccine 23 (PPSV23), con-
tain serotype-specific polysaccharides for 13 and 23 sero-
types respectively. The large-scale use of PCVs has led
to changes in disease and carriage prevalence of individ-
ual serotypes over time and geographically [11–13].
These changes have increasingly led to non-vaccine type
(NVT) serotypes emerging. For this reason, previous
publications have stressed the need to assess and under-
stand the invasive disease potential of both vaccine type
(VT) and NVT serotypes to help guide future vaccine
design [6, 9].
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Serotypes differ in their ability to cause severe disease
[14–18] and there is a correlation between polysacchar-
ide production and case-fatality rates of serotypes in
humans [19]. Pneumococcal strains with larger capsules
are also more virulent in animal models [14, 20]. Previ-
ously we have shown that there is a link between sero-
type and capsule sizes in vitro in culture media and also
between serotype and growth [21, 30]. In vitro studies
with laboratory media such as brain heart infusion broth
(BHI), show typical pneumococcal growth has an expo-
nential and a lysis phase. The lysis phase has previously
been reported to be due to cell death mainly induced by
the pneumococcal autolysin LytA; see review [22]. An-
other study, however, showed that autolysis is caused by
accumulation of hydrogen peroxide due to the expres-
sion of the spxB gene resulting in apoptosis [15].
Supporting the experimental findings, studies show
that, although the outcome of pneumococcal disease can
be affected by factors such as age, immunodeficiency
and other host characteristics, even when controlling for
these factors, certain serotypes are associated with more
severe disease [16–18]. Similarly, other epidemiological
studies have linked serotype to mortality rates in patients
and to invasive disease potential [1, 7–9, 23].
It is not fully understood how the different serotypes
are responsible for differences in disease severity. There-
fore, here we studied the growth behaviour and capsule
size of different serotypes in human cerebrospinal fluid
(hCSF) rather than culture media to reflect more closely
the environment the bacteria would encounter in a men-
ingitis patient. Although other studies have looked at
hCSF parameters in the setting of pneumococcal menin-
gitis [24–27], data about the behaviour of S. pneumoniae
in hCSF in vitro is scarce. We tested whether differences
in ability to grow in hCSF in vitro and differences in cap-
sule size correlate with serotype-specific disease severity.
Results
The growth pattern of S. pneumoniae in hCSF differs from
that in culture medium
To determine whether S. pneumoniae is able to grow and
how it behaves in hCSF in vitro, we performed growth
analysis over 40 h of the strain 106.66 (serotype 6B) in
BHI + FCS and hCSF. The growth pattern of strain 106.66
in hCSF lacked a discernible exponential phase and the
autolysis phase typically seen when grown in BHI + FCS
medium (Fig. 1). In hCSF, we observed an extended
straight line of growth of 106.66 which plateaued after ~
35 h (Fig. 1). This observation was consistent for 106.66
and all its capsule switch mutants which grew in hCSF
(Additional file 1: Figure S2). No growth was observed in
control wells containing hCSF with no inoculum (results
not shown). To test whether this pattern of growth was
due to limited nutrition, the bacteria were grown in CDM.
The ODmax in CDM was noticeably lower than in BHI +
FCS but the exponential phase and the autolysis phase
were still present (Additional file 1: Figure S3). To test
whether a factor in hCSF was inhibiting growth, the same
strain was grown in a 1:1 mixture of BHI + FCS and hCSF.
The growth in the 1:1 mixture did not differ from that in
BHI + FCS (Additional file 1: Figure S3).
Capsule aids growth in hCSF
To determine the effect of capsule on growth of S. pneu-
moniae in hCSF, we compared the growth of the wild
type strain 106.66 with its capsule deletion mutant
Fig. 1 Growth pattern of S. pneumoniae wild type strain 106.66 in BHI + FCS and hCSF over 40 h. In BHI + FCS, 106.66 shows the typical
exponential phase followed by a peak OD450nm followed by an autolysis phase. In hCSF, 106.66 lacked the typical exponential phase, peak
OD450nm and the following autolysis phase. Each data point represents an average of 3 independent experiments
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(106.66 Janus) as well as the wild type strain 51,114 L
with its nonencapsulated spontaneous mutant, 51,114 S.
Both the encapsulated strains 106.66 (serotype 6B) and
51,114 (serotype 19F) grew in hCSF to a higher OD than
their nonencapsulated mutants (Fig. 2). This pattern was
observed in hCSF from both patients tested. To check
that this difference was not due to the bacteria with cap-
sules being larger and therefore having a higher OD for
the same number of bacteria than the nonencapsulated
bacteria, the two phenotypes of strain 51,114 were
grown again, in hCSF from a third patient, and plated
out at 6 h. The CFU count was higher for the encapsu-
lated strain (51,114 L) than its nonencapsulated mutant
(51,114 S) confirming more bacterial growth when the
bacteria possessed a capsule (Additional file 1: Figure S4).
High carriage serotypes have a growth advantage in hCSF
A previous publication showed that a 7F capsule switch
mutant of strain 106.66 caused less severe disease in an
animal model than its wild type serotype 6B parent [28].
In our study, switching the capsule to 7F significantly re-
duced ODmax in hCSF (Fig. 3a). When comparing the 6B
to additional serotypes we found significant differences
between serotypes 6B, 18C and 14; 19F and 18C; 23F,
14, and 7F; 9 V and 7F; 15B/C and 7F (p-value < 0.04).
When pooling data for the four high carriage and four
low carriage serotypes (defined according to our previ-
ous publication [29]), the low carriage serotypes reached
significantly lower ODmax values in hCSF than the high
carriage serotypes (Fig. 3b). No significant differences
were observed when comparing the serotypes in BHI +
FCS (Additional file 1: Figure S5). To confirm that dif-
ferences in OD between serotypes in hCSF were really
due to growth not bacterial size, CFU count was deter-
mined at 6 h and was higher for 6B and 19F than 14 and
7F (Additional file 1: Figure S6).
Growth in hCSF correlates with case-fatality rate
Since CFR is associated with serotype [8, 9] and we show
that growth in hCSF is affected by capsule type; we
looked whether growth in hCSF correlated with CFR by
serotype. We observed a positive correlation between
CFR of serotypes and the ODmax in hCSF (R
2 = 0.6174,
p-value = 0.0208) (Fig. 4).
Capsule size is serotype-specific in hCSF
We observed no difference in capsule size between any
of the strains in BHI + FCS but in hCSF we observed a
significant difference of capsule size between the sero-
type 6B wild type and the 7F and 19F capsule switch
mutants (Fig. 5). The capsule size of both the 7F and the
19F capsule switch mutants were significantly greater in
hCSF than the 6B serotype (Fig. 5c) and that of the 19F
capsule switch mutant was significantly greater than that
of the 7F (Fig. 5c).
Discussion
We demonstrated that S. pneumoniae was able to grow
in hCSF in vitro and that, contrary to the typical expo-
nential growth pattern seen in BHI + FCS, the growth
Fig. 2 Growth of S. pneumoniae strains with and without capsule in hCSF over 40 h. Strain 106.66, its capsule deletion mutant (106.66 Janus) and
the clinical isolate 51,114 with and without capsule (51,114 nonencapsulated) in hCSF over 40 h. Each data point represents an average of 3
independent experiments
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pattern in hCSF appeared as an extended straight line and
lacked the autolysis phase. We speculated that the pattern
may be due to the low nutritional composition of hCSF
and because of the static in vitro environment where the
hCSF is not replaced regularly as it would be under
physiological conditions. However, during growth in low
nutrient CDM with similar glucose level to hCSF, expo-
nential growth and autolysis phase were still present. A
previous study which analyzed the growth of E. coli, S.
aureus, L. monocytogenes, K. pneumoniae, S. epidermidis
as well as group B β-hemolytic streptococcus in hCSF
hypothesized that hCSF inhibits the growth of these bac-
teria species [30]. We did not observe a reduction of
growth of S. pneumoniae in a 1:1 mixture of hCSF and
BHI + FCS compared with BHI + FCS alone. We therefore
did not find evidence for pneumococcal inhibiting factors
in hCSF, although we cannot rule out that any inhibitor
diluted by half is below the concentration required to have
a detectable effect. We speculate that the lack of autolysis
may be due to low expression of either the spxB gene en-
coding pyruvate oxidase which produces hydrogen perox-
ide that may be a trigger for pneumococcal apoptosis [31]
Fig. 3 Growth maximum OD values of wild type strain 106.66 and capsule switch mutants in hCSF. a Maximum OD values in hCSF of wild type
strain 106.66 and its capsule switch mutants. Black indicates high carriage prevalence, grey indicates low carriage prevalence according to [30], p-
value < 0.04 (b) The mean of the maximum OD for all strains of high carriage serotypes (19F, 6B, 9 V and 23F) was greater than the mean of the
maximum OD for all strains of the low carriage serotypes (15B/C, 18C, 14 and 7F), p-value < 0.0001. Error bar represent the standard error of the
mean of three independent experiments
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and/or the lytA gene which encodes the main autolysin
degrading the cell wall and leading to pneumococcal lysis
[32] but this has yet to be determined.
Presence of capsule enhanced growth in hCSF as fol-
lowing loss of capsule, growth was greatly reduced. This
is in line with the literature which states that although
nonencapsulated strains have been noted in IPD cases
[33–35], these findings are very rare [36] and suggests
that the capsule plays a fundamental role in survival and
ability to grow in hCSF thereby contributing to meningitis.
Our results also showed that serotype influences the
growth of S. pneumoniae in hCSF in vitro. Using one S.
pneumoniae strain and comparing it to its mutants with
insertion of different capsule genes to express different
serotypes, we were able to study the effect of serotype in
the absence of confounding effects of different genetic
backgrounds. As we found previously in culture medium
[30], we found that capsule type determines the growth
phenotype in hCSF. The results also support another
observation that capsule type rather than the genetic
background is the main determinant of survival [37].
Furthermore, we noticed a pattern that serotypes catego-
rized as invasive serotypes tended to have very poor
growth in hCSF whereas serotypes categorized as high
carriage serotypes tended to grow better in hCSF and
that this correlates with serotype CFR. These results add
to the evidence that the capsule plays an important role
in severity of disease as high carriage serotypes are also
often associated with more severe disease [8, 9]. The 19F
serotype, which has repeatedly been associated with
meningitis, reduced quality-adjusted life years, and
increased CFR (reviewed in [8]), particularly showed a
better ability to grow in hCSF than any of the other se-
rotypes tested.
We also found significant differences in capsule size be-
tween 19F, 7F and 6B serotypes in hCSF. Of note, the 19F
serotype, which is associated with severe disease [8, 9],
and which grew best in hCSF, had the thickest capsule.
Contrary to our expectations, however, serotype 7F also
had a thicker capsule than 6B in hCSF even though 6B
grew better than 7F as measured by both maximum
optical density and number of colonies. In our previous
publication, with these serotypes in an animal model, 6B
appeared to have a thicker capsule than the 7F serotype.
However, these differences may be explained due to
physiological differences between rats and humans or be-
cause of the time point of sampling. A simpler capsule
may be less metabolically demanding to synthesize allow-
ing rapid growth and thick capsule in hCSF [30].
A limitation of our study is that, although growth was
monitored in human CSF, all analyses were performed
in vitro. We collected and froze the hCSF samples as soon
as possible following lumbar puncture and did not refreeze
samples but we cannot exclude the possibility that the com-
position of the hCSF changed during the time after removal
from the patients. In vivo there would be a turnover of
hCSF which would likely provide more nutrients to the
bacteria. Therefore, with our in vitro experiments we may
be underestimating the amount of pneumococcal growth in
hCSF. This could be overcome by development of an
in vitro system where the hCSF is replenished, if sufficient
hCSF was available. Another major difference between our
experiments and the situation in vivo is the absence of im-
mune cells in our system. As meningitis progresses the
number of immune cells in the hCSF might be expected to
increase and any effect of this on bacterial growth and cap-
sule thickness is not accounted for in our experiments. We
deliberately chose to use hCSF from patients without in-
flammation to model early disease when pneumococci first
reach the hCSF. However, it would also be interesting to
study pneumococcal growth and capsule thickness in hCSF
from patients with meningitis as we speculate that these
may be affected by a nutritionally richer environment. We
have made the assumption that the hCSF we have used is a
model of healthy hCSF but the samples were taken from
patients rather than healthy volunteers, although routine
parameters were within normal ranges. Due to availability
of samples, our experiments were limited to hCSF from 3
patients. Further testing in hCSF from more patients would
be beneficial, although we note that the results we found
were consistent between the hCSF of the three different
patients.
A further limitation is the number of pneumococcal
strains tested. It would be interesting to expand the study
to further high and low carriage serotypes including those
Fig. 4 Correlation between case-fatality rate and maximum OD450nm
of different serotypes. For each serotype (6B n = 2, 7F n = 2, 14 n = 1;
9 V n = 2, 15B/C n = 1; 18C n = 2; 23F n = 1; 19F n = 3), the average
ODmax reached in hCSF was plotted against the case-fatality rate
obtained from a previous publication [7]. A positive correlation was
found (R2 = 0.7645, p-value = 0.0100)
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with large mucoid capsules such as serotypes 3 and 8 if the
challenges of making capsule switch mutants of such sero-
types could be overcome. However, we note that the pat-
tern of growth, particularly the lack of autolysis was
consistence for all strains tested.
Conclusions
We found that in hCSF there was no autolysis and that sero-
type influenced growth and capsule size. Growth correlated
positively with previously published serotype CFR ranges.
Our findings contribute to the understanding of the role of
serotype in pneumococcal disease, particularly meningitis.
We further suggest that growth and capsule size in hCSF
in vitro may be useful attributes to predict severity of disease
caused by different serotypes to guide future vaccine design.
Methods
Bacterial strains
Swiss pneumococcal strain 106.66 (serotype 6B) is a clinical
isolate from the nasopharynx of a child from a nationwide
Fig. 5 Capsule sizes of strains after 9 h of incubation in BHI + FCS or hCSF. a FITC-dextran exclusion images of wild-type strain 106.66 serotype 6B
(a,d) and of capsule switch mutant 106.66cps208.41 (serotype 7F) (b,e) and 106.66cps111.46 (serotype 19F) (c,f) and after 9 h of incubation in
BHI + FCS (a,b,c) and hCSF (d,e,f). All images are to the same scale, taken using a 100X objective, and the scale bar indicates 10 μm. b and c show
the mean area of bacterium (square pixels) after 9 h of incubation of wild-type strain 106.66 serotype 6B compared to its capsule switch mutants
106.66cps208.41 serotype 7F and 106.66cps111.46 serotype 19F in b BHI + FCS or c hCSF. No significant difference was observed between any of
the strains in BHI + FCS. Significant differences were found when comparing 106.66 with 106.66cps208.41 (p-value = 0.0008) and 106.66cps111.46
(p-value < 0.0001) and when comparing 106.66cps208.41 and 106.66cps111.46 (0.026). Each symbol represents one image containing at least 2
bacteria. Error bars represent the standard error of the mean of three independent experiments
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surveillance program collecting nasopharyngeal and inva-
sive isolates [5, 38]. 106.66, its capsule deletion mutant
(106.66 Janus) and several capsule switch mutants were
used. 106.66 Janus and all capsule switch mutants are listed
in Additional file 1: Table S1 (serotype 6B (n = 1), 7F (n =
2), 14 (n = 1), 9 V (n = 2), 15B/C (n = 1), 18C (n = 2), 23F
(n = 1) and 19F (n = 3)). Production of the 106.66 capsule
switch mutants and the 106.66 capsule deletion mutant
(106.66 Janus) are described in a previous publication [30].
Additionally, a clinical isolate of serotype 19F (strain
51,114) recovered from the hCSF of an adult meningitis
patient in 2017 from the South African GERMS national
laboratory based surveillance program was provided by
the National Institute for Communicable Diseases
(NICD) in Johannesburg. This serotype was chosen due
to its repeated association with meningitis and high CFR
[8, 9]. Plating out of the frozen stock of South African
serotype 19F strain 51,114 on Columbia sheep blood
agar (CSBA) plates overnight (37 °C, 5% CO2) showed
two colony phenotypes: large (51,114 L) and small col-
onies (51,114 S) with appearance of encapsulated and
nonencapsulated pneumococci, respectively. The two
phenotypes were separated and purified by three consecu-
tive passaging steps where each time one single colony was
picked and streaked on a CSBA plate. Separation as well as
presence or absence of capsule was confirmed by serotyp-
ing and FITC-dextran exclusion assay (Additional file 1:
Figure S1). Both phenotypes were confirmed to have the
same genetic background (MLST 347) by multilocus
sequence typing. This publication made use of the Strepto-
coccus pneumoniae MLST website (https://pubmlst.org/
spneumoniae/).
For all strains, Quellung reaction was used to confirm
serotype. The serotypes were categorized as low carriage
/ high invasive potential (7F, 14, 15B/C and 18C) or high
carriage / low invasive potential (6B, 19F, 9 V and 23F)
according to a previous paper [30].
Human cerebrospinal fluid
Residual hCSF from three adult patients undergoing
routine lumbar puncture in 2018 and 2019 due to idio-
pathic intracranial hypertension (non-inflammatory) was
used for growth and capsule analysis. Lumbar puncture
was performed by trained personnel. hCSF samples and
related patient data were anonymized by the treating
physician prior to any research use in accordance with
the Swiss Human Research Law (Humanforschungsge-
setz, HFG). Routine hCSF parameters were within normal
ranges for all samples (glucose = 4.9 ± 1.6mM; protein =
0.25 ± 0.07 g/l; cell count = 2 /ml). Samples were stored
initially at 4 °C until collection and were aliquoted and fro-
zen at − 80 °C within 48 h after lumbar puncture. All sam-
ples were used for analysis within 3months of freezing.
They were thawed 15min before use. There was no pool-
ing of CSF samples from different patients.
Bacterial culture
Bacteria were stored at − 80 °C in Protect bacterial preservers
(Technical Service Consultants, Heywood, U.K.). Bacteria
were plated on CSBA and grown overnight in a 37 °C, 5%
CO2 atmosphere. Three to 10 colonies were picked and used
to inoculate tubes containing 5ml brain heart infusion (BHI;
Becton Dickinson and Company, le Pont de Claix, France)
supplemented with 5% fetal calf serum (FCS; Biochrom KG,
Berlin, Germany) (BHI + FCS). The culture was then incu-
bated until OD600nm reached 0.8–0.9. From this culture, a
250 μl sample was added to 750 μl fresh BHI + FCS. The cul-
ture was grown until OD600nm reached 0.4 to ensure bacteria
were in the exponential growth phase.
Bacterial growth
When bacterial culture reached OD600nm of 0.4, the cul-
ture was centrifuged for 5 min at 3000 g and the super-
natant discarded. The culture was then re-suspended in
5 ml phosphate buffered saline pH 7.4 (PBS). Growth
was assessed as described previously [30] with minimal
changes described as follows. Sterile flat-bottomed 96-
well microtitre plates (Nunclon Surface, Nunc,
Denmark) were used based on the method of Brewster
[39]. 8 μl of the PBS bacteria suspension was transferred
into 200 μl of media (BHI + FCS, hCSF or CDM). CDM
is a chemically defined medium with low nutritional
value as defined in a previous publication [40] (with 4
mM glucose instead of 5.5 mM to mimic the hCSF glu-
cose concentration). For growth in BHI + FCS and
CDM, each strain was used to inoculate three wells per
experiment. For growth in hCSF, due to limited amount
of available hCSF, one well per bacterial strain was inoc-
ulated per experiment. The plate was then incubated at
37 °C and OD450nm measured using a VERSAmax micro-
plate reader (Molecular Devices). SoftMax Pro Software,
version 5.3 was used to record measurements. OD was
measured at 30 min intervals over 40 h with 5 s of auto-
matic shaking preceding each reading. Condensation
was prevented by pre-treating the plate lid with 3ml
0.05% Triton X-100 in 20% ethanol [30]. All experiments
were performed three times on three separate days. Dif-
ferences in growth between serotypes were assessed by
comparing maximum OD450 (ODmax) over 40 h.
To determine colony forming units (CFU), dilutions of
bacterial cultures were plated onto CSBA plates and cul-
tured overnight at 37 °C, 5% CO2 atmosphere and colonies
counted the following day.
Correlation of serotype specific growth in hCSF with CFR
To analyze whether the ability to grow in hCSF in vitro
correlated with disease severity we plotted the ODmax
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that each serotype reached in hCSF or BHI + FCS over
40 h against the corresponding serotype case-fatality rate
(CFR). The CFR was taken from a previous publication
by Sjöstrom K, et al. (2006) [7] in which CFR was calcu-
lated based on data collected from 494 adult patients
with invasive pneumococcal disease.
Capsule size
The FITC-dextran method of Gates et al. [41], in which
the zone of exclusion is measured, was used for capsule
size analysis. Bacteria were cultured as described above.
After reaching OD600nm of 0.4 the culture was centrifuged
at 3000 g for 5 min. The supernatant was discarded and
the pellet re-suspended in 5ml PBS. A sample of 50 μl
bacterial suspension was used to inoculate 600 μl of BHI +
FCS or hCSF. The tubes were incubated in a water-bath at
37 °C. FITC-dextran exclusion assay was performed at
time 0 and 9 h after incubation. To perform the FITC-
dextran assay, 10 μl of the bacteria culture was removed
and mixed with 2 μl FITC-dextran (2000 kDa, Sigma; 10
mg/ml in water). The mixture was pipetted onto a micro-
scope slide and a coverslip was applied. A Zeiss Axio
Imager M1 fluorescence microscope with a 100 x object-
ive was used to view the slides. The Zeiss AxioCam HRc
camera was used for photographing the slides. Capsule
size was measured from at least 5 randomly selected bac-
terial cell bodies over five images per group of each of the
three independent images, adding up to a total of 15 im-
ages per group.
We performed FITC-dextran exclusion assays of wild
type strain 106.66 serotype 6B, its 7F capsule switch mu-
tant (106.66cps208.41) and a capsule switch mutant of
19F serotype (106.66cps111.46) due to the association of
serotype 19F with meningitis and a high CFR [8] and be-
cause it had the highest average ODmax value in hCSF.
Statistics
Statistical analysis and graphs were performed using the
GraphPad Prism software (version 7.04, GraphPad Soft-
ware). The same software was used for linear regression
analysis for which a p-value, two-tailed, of ≤0.05 was
considered significant. The comparisons of ODmax were
performed using a non-parametric Mann Whitney, two-
tailed comparison test. A value of p ≤ 0.05 was consid-
ered significant.
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